Hal N. Siegel, PhD, Chief Scientific Officer

Dr Siegel has over 20 years experience across R&D and regulatory affairs in the pharmaceutical and biotechnology industries and has participated in several successful rounds of fund-raising for venture funded as well as public companies.

Prior to joining ImmuneRegen BioSciences Inc., initially as Senior Vice President, Product Development and Regulatory Affairs in October, 2006 (and subsequently advancing to Chief Scientific Officer in 2008), he served as Vice President, Scientific and Regulatory Affairs of Zila, Inc., in Phoenix, AZ, where his responsibilities included leadership of the company’s Scientific and Regulatory Affairs programs (pertaining to a combination product and an oncology drug in Phase III clinical studies), acting as FDA liaison and establishing collaborative research studies with leading researchers in oral care, cancer or non-invasive imaging labs.

Previously, Siegel had formed Siegel Consultancy LLC, through which he served multiple life science industry clients needing ad hoc regulatory, clinical or scientific affairs expertise. He was also recruited into companies in the regulated information technology space, such as Sun Microsystems, where he served as Domain Expert to the Life Sciences Group responsible for millions of dollars of sales of hardware and services to life science companies in research, development or with commercial sales. Prior to that, at BioQ, an IT startup, he lead the MD/PhD team responsible for the identification, acquisition and integration of regulatory and scientific content into a SaaS product being developed in collaboration with IBM, Accenture and Autonomy (a European artificial intelligence company)

Siegel had spent six years at Advanced Bioresearch Associates, a boutique CRO with multiple offices nationwide. As Vice President, he opened an Arizona office to prospect and service local life science companies. Prior to that, he worked from the La Jolla, CA office providing regulatory, clinical and scientific support for the San Diego life science community, including serving as primary regulatory and scientific contact to a botanical drug company startup eventually acquired by Wyeth-Ayerst (now Pfizer). He joined ABA following regulatory affairs positions at Hybritech Inc. (an Eli Lilly company) and Iatric Corporation, where he was responsible for regulatory and compliance activities surrounding biological products and a monoclonal antibody/drug combination product.

After obtaining his Bachelor’s degree in Biology from Rensselaer Polytechnic Institute, Troy, NY and PhD in Biochemical Pharmacology from SUNY Buffalo (working with Drs. J. Craig Venter and David J. Triggle), Siegel performed post -doctoral research in the laboratory of Mark Bitensky at Los Alamos National Laboratory, Los Alamos, NM, studying non-enzymatic glycosylation in diabetes, and at the laboratory of Ronald Lukas at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center, Phoenix, AZ, studying the molecular composition and physiological roles of nicotinic cholinergic receptors. He also serves on the Board of Directors for ImmuneRegen, as well as the Phoenix Leadership group of AZBio, the Arizona life science industry trade group.